Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Casaubon who wrote (14598)	12/9/2004 1:21:43 PM
From: Biomaven	Read Replies (4) \| Respond to of 52153

Here's a very interesting situation. I personally think the chances of Barr launching "at risk" have to be small - they'd be risking $1 billion damages or more. Not sure when the right time to play this is though: Reuters Kos Sinks, Generic Drug Blamed Thursday December 9, 11:06 am ET CHICAGO (Reuters) - Shares of Kos Pharmaceuticals Inc. (NasdaqNM:KOSP - News) slumped 8 percent on Thursday after an analyst suggested Barr Pharmaceuticals Inc. (NYSE:BRL - News) could launch a copycat version of a key Kos drug earlier than expected. ADVERTISEMENT Deutsche Bank said Barr could launch a generic version of Kos's Niaspan drug as early as April of 2005. Niaspan is an extended version of the nutrient niacin that elevates levels of so-called good cholesterol. The companies have sparred in court over when Kos's patent ends. Barr spokeswoman Carol Cox said the company is leaving all options open. The companies have a February 2006 court date set for Barr's patent challenge to Kos, but, under FDA patent challenge rules, Barr could launch the product as early as April 2005. In a research note Wednesday, analyst David Steinberg said if Barr launches this early, "it would be a devastating blow to the company's earnings, with the stock falling to the $18 range." Kos shares slumped $3.32, or 8.1 percent, to $37.91 on the Nasdaq, while Barr shares rose 99 cents, or 2.4 percent, to $43.05. "We do not believe most investors have factored this risk into the current outlook for Kos," Steinberg said. Barr, as the first generic-drug company to file to make a generic version of the drug, would have exclusive rights to sell the drug for a period of time. The only recent example I know of for an "at risk" launch was for Neurontin - but there we were talking a very limited patent life. Peter Edit: Paxil and Prilosec generics were also launched at-risk, but in both cases after litigation